Efficacy of Magnetic Imaging Colonoscopy Applied to Beginner Endoscopists

NCT ID: NCT05746962

Last Updated: 2023-03-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-06

Study Completion Date

2024-10-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Magnetic endoscopic imaging (scopeguide) is known to be helpful for colonoscope insertion, especially beginner endoscopist. In this trial, study was designed to show the efficacy and safety pertinent to scopeguide use in detail.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Colorectal cancer is one of the most commonly diagnosed malignancies worldwide. Colorectal cancer screening significantly reduced the incidence and mortality, and colonoscopy is generally recognized as a standard method. Among them, magnetic endoscopic imaging (MEI, Scopeguide, Magnetic Enhanced Instrument, Olympus, Japan) is a non-radiological imaging instrument that can display the three-dimensional configuration and position of the colonoscope in the abdominal cavity in real time. This study aims to investigate the effectiveness of colonoscopy by measuring the insertion-related index of the colonoscopy according to the scope guide for only beginners of endoscopy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colonic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group that does not use the scopeguide screen

The control group should remove the looping of colonoscope by looking at the general colonoscopy screen The control group cannot use scopeguide screen Scopeguide screen is blinded by an opaque wrapping paper

Group Type ACTIVE_COMPARATOR

ScopeGuide Navigated Colonoscope

Intervention Type DEVICE

colonoscopes equipped with ScopeGuide

Group using the scopeguide screen

The experimental group uses a general endoscopic image during colonoscopic insertion The experimental group should remove the looping of colonoscope by looking at the scopeguide screen

Group Type EXPERIMENTAL

ScopeGuide Navigated Colonoscope

Intervention Type DEVICE

colonoscopes equipped with ScopeGuide

Navigation screen

Intervention Type DEVICE

ScopeGuide's 3D visualisation screen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ScopeGuide Navigated Colonoscope

colonoscopes equipped with ScopeGuide

Intervention Type DEVICE

Navigation screen

ScopeGuide's 3D visualisation screen

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 19-80
* the patient who visit to examine the colonoscopy

Exclusion Criteria

* the patient who has a pacemaker
* the patient who has electronic devices in the body
* bowel obstruction and bleeding
* glomerulus filter rate \< 30
* inflammatory bowel disease, pregnancy
* previous history of bowel resection and abdominal surgery
* who refuse to write the informed consent
* previous history of allergic reaction to sedative drugs and beans, egg
* SBP \<80, SpO2\<90
Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Korea University Anam Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Keum, Bo Ra

Professor of Division of Gastroenterology and Hepatology, Department of Internal Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bora Keum

Role: STUDY_DIRECTOR

[email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Han Jo Jeon

Seoul, Seong Buk Gu, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bora Keum

Role: CONTACT

+82-2-920-6555

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Han Jo Jeon

Role: primary

+82-2-920-6555

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022AN0126

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.